The Utility of Rapid On-Site Evaluation during Bronchoscopic Biopsy: A 2-Year Respiratory Endoscopy Central Experience

Hansheng Wang,1,2 Na Wei,1,2 Yijun Tang,1,2 Yunyun Wang,3 Guoshi Luo,1,2 Tao Ren,1,2 Chang Xiong,1,2 Hongbo Li,1,2 Meifang Wang,1,2 and Xin Qian1,2

1Department of Pulmonary and Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000 Hubei, China
2Respiratory Endoscopy Center, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000 Hubei, China
3Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000 Hubei, China

Correspondence should be addressed to Meifang Wang; wmfpps02@hotmail.com and Xin Qian; xinqiantj@163.com

Received 3 March 2019; Revised 10 July 2019; Accepted 8 August 2019; Published 8 December 2019

1. Background

In recent years, rapid on-site evaluation (ROSE) has been rapidly popularized in endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) [1–5], or fine needle aspiration biopsy (FNA) [6–8] for assessing materials’ adequacy and categorizing diagnosis during biopsy procedure. Chandra et al. [9] and Nakajima et al. [2] demonstrated that ROSE is critical for assessing the adequacy of cytological smears and cytology is comparable to histology in the diagnosis of lung lesions. In addition, Fassina et al. [8] reported a satisfactory overall agreement of 71.4% was achieved in differentiating the cancer histological types in fine needle aspiration (FNA) for ROSE, and Nakajima et al. [2] reported a concordance rate of ROSE and final pathologic diagnosis of 94.3% in endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

The use of ROSE may allow an earlier termination of the procedure based on the confirmation that diagnostic tissue has been retrieved, and may, therefore, improve diagnostic sensitivity by redirecting sampling to adjacent sites in the event of a negative ROSE finding [10, 11]. In addition, ROSE can help bronchoscopists determine whether additional specimen needs to be collected for further ancillary studies, such as...
immunochemistry, molecular detection, and microbiology [8]. Visible lesions are biopsied under direct vision using fiber optic bronchoscopy (FOB); however, the quality and adequacy of biopsy materials are not known. Because ROSE has good intermodality agreement with histopathology and can provide the bronchoscopist with an onsite preliminary diagnosis, it may solve these problems. However, the utility of ROSE during bronchoscopy biopsy under direct vision is rarely reported, and so its role has remained unclear. We conducted this prospective randomized study to further clarify the role of ROSE in assessing materials’ adequacy and categorizing diagnosis during biopsy procedure.

2. Materials and Methods

All 651 patients who underwent bronchial biopsy combined with ROSE in TaiHe Hospital (Shiyian, Hubei, China) were enrolled in the study. Informed consent was obtained from all patients, and FOB biopsy was performed by a bronchoscopist. Study was approved by the TaiHe Hospital Ethics Committees. ROSE was performed in the presence of a cytopathologist in the procedural room of bronchoscopy when possible, cytopathologist immediately interpreted whether the sample was negative (no malignant cells) or positive (definitive cytopathologic evidence of malignancy or special infection evidence). A small portion of each biopsy pass was placed on a slide, smeared, and stained with Diff-Quik for onsite analysis. Slide preparations were performed by the procedural pulmonologist or by an assistant who was a member of the procedural team. A smear was considered adequate if it contained an abundance of preserved cells or showed sufficient cellularity compatible with the clinical and/or radiological findings. Inadequate material was subjected to re-biopsy instantaneously. The tissue was fixed with formalin and sent to the pathology department for immunohistochemical stains and molecular studies. We categorized the histological and cytological subtypes in accordance with the IASLC/ATS/ERS [12]. Our diagnoses include definitely adenocarcinoma (AC), favor AC, definitely SqCC, favor SqCC, and NSCLC-NOS, we classified definitely adenocarcinoma (AC) and favor AC into AC, and definitely SqCC, favor SqCC into SqCC in our research. The diagnosis was made on the basis of histologic characteristics—clear-cut evidence of pearl formation, keratinization for SqCC differentiation, and glandular structure for AC differentiation, then IHC evaluation staining intensity was graded as focal and weak, diffuse and strong, negative. Final diagnosis was determined with p63, TTF-1, and neuroendocrine immunostain for all cases. p63(+) was accepted for an SCC, TTF-1(+) was accepted for an ADC. Diagnosis was assigned as adenosquamous cell carcinoma, when both p63 and TTF-1 are positive. If cytology was NSCLC-NOS but histology was SqCC or AC, the criterion for final diagnosis was accepted on the basis of histology. If histology was NSCLC-NOS but cytology was SqCC or AC, the final diagnosis was accepted on the basis of histology also. If IHC was not available, histology and final diagnosis was NSCLC-NOS.

When granulomatous inflammation with necrosis was observed during ROSE, biopsy specimen was considered sufficient and supported for tuberculosis diagnosis by ROSE.

After that histopathology, Zeihl–Neelson (ZN) stains combined with PCR were performed for final diagnosis of tuberculosis. Trachea and bronchi fungal infections are mainly aspergillus in our study, visible aspergillus hyphae provide evidence for cytology or histopathology diagnosis, microbial cultures of specimen was needed.

3. Results

3.1. Cases. Between January 2017 and January 2019, 651 cases were enrolled, of which 502 were men and 149 were women. The median age was 58.7 years (range, 13–84 years). During bronchoscopic examination, of 651 patients, 284 (43.6%) showed visible bronchial neoplasms and 367 (56.4%) showed bronchial mucosal lesions, as shown in Table 1.

3.2. Onsite Evaluation. Of the 651 smears, 618 (94.9%) were adequate and 33 (5.1%) were inadequate because of excessive blood or necrosis. Among the 618 satisfactory cases, 46.4% (287/618) were adequate on the first biopsy pass, 30% (185/618) on the second pass, and 10.2% (63/618) on the third pass. The remaining cases included 5.8% (36/618), 2.5% (16/618), 4% (25/618), and 1% (6/618) obtained during the fourth, fifth, sixth, and seventh passes, respectively. An average of two biopsy passes was required to obtain adequate specimens during ROSE (Figure 1).

3.3. Diagnostic Categories of Malignancy. Good overall consistency was achieved in categorizing the histological types of malignancy (344/438; 78.5%) (Table 2). There were 126 cases of squamous cell carcinoma (SCC) confirmed by ROSE and pathology; ROSE and pathological diagnosis results were consistent (Kappa = 0.718, p < 0.05), with a PPV of 74.1%, NPV of 92.8%, specificity of 86.0%, and sensitivity of 85.7%. For adenocarcinoma (AC), ROSE and pathological diagnosis were consistent (Kappa = 0.662, p < 0.05), with a PPV of 69.6%, NPV of 93.7%, specificity of 89.3%, and sensitivity of 80.6%. In small cell lung cancer (SCLC), ROSE and pathological diagnosis were well correlated.

Table 1: Characteristics of patients and lesions.

| Parameter               | Value       |
|-------------------------|-------------|
| Number of patients      | 651         |
| Gender (male/female)    | 502/149     |
| Age (years) (mean ± SD) | 58.7 ± 11.2 |
| Type of lesion (%)      |             |
| Neoplasm                | 43.6% (284/651) |
| Mucosal lesion          | 56.4% (367/651) |
(Kappa = 0.955, $p < 0.05$), with a PPV of 95.9%, NPV of 99.2%, specificity of 98.0%, and sensitivity of 95.3%. In addition, for the same biopsy specimen, there were 35 cases of ROSE and pathology consistently diagnosed as NSCLC-NOS. However, ROSE showed poor diagnostic accuracy for specific tumors such as adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), sarcomatoid carcinoma (SARC), and fetal lung adenocarcinoma (FLAC). For metastases, ROSE could only identify suspicious findings, whereas it could not distinguish the source of metastasis. As shown in Table 1,
the ROC curve of ROSE for the diagnosis of tuberculosis was 0.893 (95% CI: 0.83–0.96, \( P < 0.001 \)). Of five cases of mycosis confirmed by pathology, three were correlated with ROSE (Kappa = 0.744, \( P < 0.001 \)), the area under the ROC curve of ROSE for the diagnosis of mycosis was 0.80 (95% CI: 0.00–1.00, \( P < 0.001 \)). For acute/chronic nonspecific inflammation, Cohen’s kappa demonstrated a satisfactory agreement of 0.815 (\( P < 0.001 \)) between histopathology and cytology as shown in Table 3.

3.4. Benign Diagnosis. Tuberculosis was diagnosed in 57 patients, of which 46 showed a consistent diagnosis by ROSE (Kappa = 0.814, \( P < 0.001 \)). Diagnostic specificity and sensitivity were 80.7% and 98.0%, respectively. The area under the ROC curve of ROSE for the diagnosis of tuberculosis was 0.893 (95% CI: 0.83–0.96, \( P < 0.001 \)). Of five cases of mycosis confirmed by pathology, three were correlated with ROSE (Kappa = 0.744, \( P < 0.001 \)), the area under the ROC curve of ROSE for the diagnosis of mycosis was 0.80 (95% CI: 0.00–1.00, \( P < 0.001 \)). For acute/chronic nonspecific inflammation, Cohen’s kappa demonstrated a satisfactory agreement of 0.815 (\( P < 0.001 \)) between histopathology and cytology as shown in Table 3.

Table 4 shows the cytopathological correlation and diagnostic accuracy in various lung lesions. The diagnostic accuracy of ROSE was 89.4% for SCC, 80.6% for AC, and 95.3% for SCLC, similar to that of histology.
ROSE cytology and histology were comparable, and ROSE needle aspiration biopsy specimens by ROSE, and showed that lesions by bronchial lavage fluid, brush, TBNA, and percutaneous ultrasound or imaging was needed for detecting the location of lesions. Conversely, lesions were visible during FOB biopsy, and an experienced bronchoscopist detected suspicious lesions directly.

4. Discussion

In this study, we demonstrate that ROSE ensures the quality of biopsy specimens during FOB procedure, and the results of ROSE correlated well with the final pathological diagnosis based on hematoxylin and eosin (H&E) staining of biopsy samples of FOB.

Although technical advances in histopathology have reduced the processing time for small biopsies to a few hours [13], cytology remains the method of choice for an immediate assessment of sample adequacy, whereas biopsies can be used for different purposes [14]. The proportion of inadequate specimens reportedly ranges from 2.7% to 14.3% during FNA biopsy [6, 15, 16], consistent with our finding of 5.1% (33/651) inadequacy. Koul et al. [17] reported that only 11% of cases show adequate materials on first FNA, and an average of 3.5 biopsy passes required to obtain adequate material during FNA; however, our data suggested that 46.6% of the cases had adequate materials on first biopsy, 76.6% had adequate materials on second biopsy, and 86.6% satisfactory samples were obtained on third biopsy. A possible reason for this result was that lesions could not be visualized directly during FNA, and ultrasound or imaging was needed for detecting the location and size of lesions. Conversely, lesions were visible during FOB biopsy, and an experienced bronchoscopist detected suspicious lesions directly.

Considering patients’ safety and cost effectiveness, studies suggest that ROSE can quickly evaluate the adequacy of TBNA or FNA samples [15, 18, 19], eliminate unnecessary biopsies, help reduce costs, and avoid or reduce complications [11, 20, 21]. The present study showed that using FOB combined with ROSE, adequate specimens were obtained in 86.6% of patients in 3 biopsies, suggesting that this regimen is appropriate for FOB biopsy.

Whether lung lesions can be accurately diagnosed using ROSE remains controversial [9]. Therefore, in the present study, we combined bronchial FOB biopsy with ROSE, and analyzed the diagnostic accuracy of specimens for benign and malignant lung diseases. Chandra et al. [9] compared diagnosis by bronchial lavage fluid, brush, TBNA, and percutaneous needle aspiration biopsy specimens by ROSE, and showed that ROSE cytology and histology were comparable, and ROSE may be superior to histopathology for the diagnosis of lung tumors. In the present study, evidence of malignancy was not obtained by histology in 24 lung cancer patients, whereas ROSE detected cancer cells in these patients. Further analysis by CT-guided percutaneous lung puncture, thoracoscopic pleural biopsy, and TBNA confirmed the presence of lung cancer in the 24 patients. One possible reason for this discrepancy is that biopsy specimens contain fewer malignant tissue components, whereas they are sufficient for cytological smears. Alternatively, pathological sections may have failed to effectively obtain lesion tissue. Ravaiolli et al. [22] showed that TBNA combined with ROSE is useful for the rapid diagnosis of lung cancer, as it not only allows evaluation of the adequacy of TBNA needle biopsy specimens, but also enables the classification of lung cancer [23, 24]. Celik et al. reported that ROSE has high diagnostic yield over subclassification of NSCLC-NOS [24], and cytology, with or without cell block, successfully subclassifies NSCLC-NOS cases and can be a substitute for IHC in resource-poor laboratories and in low-income countries [23]. In our present study, there was good agreement between ROSE and final pathology for SCLC. The diagnostic accuracy of 96.8% was in agreement with reports by Fassina et al. [8] and Ravaiolli et al. [22], who reported an overall accuracy for small cell carcinoma of 90–97%. In addition, the ROSE results for SCC and AC were consistent with the final pathological diagnosis, but with a low Kappa value. Poorly differentiated SCC or AC, however, displays some features that may be confused with other poorly differentiated neoplasms [25]. It is not always possible based on morphology alone to distinguish these neoplasms from poorly differentiated neoplasms in limited samples [26]. The characteristics of small cell carcinoma cells are more obvious, as cancer cells are arranged in a row and crowded, the cytoplasm is smaller or even absent, and the nucleus has a salt and pepper appearance, with a nuclear model (Figure 2); therefore, the diagnostic accuracy and pathological consistency are better.

Reactive changes in bronchiolar epithelium might be sometimes pronounced, making it difficult to distinguish these from malignant epithelial cells, but reactive atypia in the bronchiolar epithelium is characterized by loose sheets of bronchiolar cells with moderate nuclear enlargement, irregularity, and hyperchromasia. Usually, these atypical

### Table 4: Cyto-histopathological correlation in lung lesions.

| Diagnosis               | ROSE (number of cases) | Histology (number of cases) | Final diagnosis (number of cases) | Diagnostic accuracy of histology (%) | Diagnostic accuracy of ROSE (%) |
|-------------------------|------------------------|------------------------------|-----------------------------------|--------------------------------------|---------------------------------|
| SCC                     | 167                    | 147                          | 163                               | 90.2                                 | 87.1                            |
| AC                      | 125                    | 108                          | 115                               | 93.9                                 | 81.7                            |
| NSCLC                   | 52                     | 49                           | 52                                | 100                                  | 71.4                            |
| SCLC                    | 98                     | 97                           | 95                                | 98.9                                 | 96.9                            |
| Other malignancy        | 2                      | 6                            | 6                                 | 100                                  | 33.3                            |
| Metastasis              | 0                      | 20                           | 20                                | 100                                  | 0                               |
| Tuberculosis            | 48                     | 57                           | 57                                | 100                                  | 84.2                            |
| Mycosis                 | 3                      | 5                            | 5                                 | 100                                  | 60                              |
| Granulomatous           | 2                      | 4                            | 4                                 | 100                                  | 50                              |
| Acute/chronic nonspecific inflammation | 86 | 87                           | 87                                | 100                                  | 98.9                            |
| Atypical hyperplasia    | 3                      | 3                            | 3                                 | 100                                  | 100                             |

BioMed Research International
reactive cells occur as a few dispersed cells or few small cell clusters, which helps to avoid a diagnosis of malignancy during ROSE [27, 28]. In addition, there is a difference between alveolar phagocytes and lung adenocarcinoma, pulmonary macrophages with abundant foamy cytoplasm and frequent intracytoplasmic carbon particles [27, 28]. Adenocarcinoma with signet ring, adenocarcinoma is the most common primary lung tumor and displays a variety of morphological features. Most tumors have acinar, papillary, or micropapillary features, although the acinar type is the most common [27, 28].

The features of tuberculosis under the microscope include granulomatous inflammation, necrosis, mixed lymphocytes and epithelial-like cells, and Langhans giant cells [29], sarcoidosis characterized by nonnecrotizing epithelioid cell granulomas and different from granulomatous inflammation of tuberculosis [28]. For Aspergillus and Cryptococcus, accurate diagnosis is possible if the fungus is identified. Therefore, fungal and tuberculosis infections can be accurately diagnosed onsite by experienced pathological cytologists, thus gaining time for timely clinical treatment. Although ROSE has many advantages, there are also disadvantages such as the need for a professionally trained cytopathologist on site [9].

In conclusion, ROSE can provide guidance for the bronchoscopist to obtain adequate lesion specimens during FOB biopsy and can provide an onsite preliminary diagnosis especially in cases showing an inconclusive macroscopic appearance. Because ROSE and pathology have their own advantages and disadvantages, they can complement each other to improve the accuracy of diagnosis.

5. Conclusions
In this study, we demonstrated that ROSE technique allows bronchoscopists to obtain viable and adequate material for the diagnosis of histopathology, and provides them with an onsite preliminary diagnosis especially in cases with inconclusive macroscopic appearance. ROSE and pathology should be used in combination to increase the accuracy of diagnosis.

Abbreviations

ROSE: Rapid on-site evaluation
FOB: Fiber optic bronchoscopy
SCC: Squamous cell carcinoma
AdC: Adenocarcinoma
SCLC: Small cell lung cancer
EBUS-TBNA: Endobronchial ultrasound-guided transbronchial needle aspiration
FNA: Fine needle aspiration biopsy
ROC: Receiver operator characteristic
ACC: Adenoid cystic carcinoma
MEC: Mucoepidermoid carcinoma
SARC: Sarcomatoid carcinoma
FLAC: Fetal lung adenocarcinoma
CT: Computed tomography.

Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethical Approval
This study was approved by the Taihe Hospital Ethics Committees (2018KS017) and was performed in accordance with the principles of Good Clinical Practice following the Tri-Council guidelines. All patients or their substitute decision makers provided written informed consent prior to patients.

Consent
Written consent has been obtained for all participants or their substitute decision makers.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Conception and design: Hansheng Wang, Meifang Wang. Acquisition of data: Na Wei, Yunyun Wang. Analysis and interpretation of data: Xin Qian, Guoshi Luo. Drafting or revisiting the article: Yijun Tang, Tao Ren, Chang Xiong and Hongbo Li. Hansheng Wang and Na Wei are contributed equally to this work.

Acknowledgments
We would like to acknowledge all members of the department of Pulmonary and Critical Care Medicine, Taihe Hospital, Hubei University of Medicine. This work was supported by Taihe Hospital Research Program (2017JXM047), and Educational Commission of Hubei Province of China (B20122414, Q20111206).

References
[1] M. Oki, H. Saka, C. Kitagawa et al., “Rapid on-site cytologic evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing lung cancer: a randomized study,” Respiration; International Review of Thoracic Diseases, vol. 85, no. 6, pp. 486–492, 2013.
[2] T. Nakajima, K. Yasufuku, F. Saegusa et al., “Rapid on-site cytologic evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for nodal staging in patients with lung cancer,” The Annals of Thoracic Surgery, vol. 95, no. 5, pp. 1695–1699, 2013.
[3] D. Jain, T. C. Allen, D. I. Aisner et al., “Rapid on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspirations for the diagnosis of lung cancer: a perspective
from members of the pulmonary pathology society," *Archives of Pathology & Laboratory Medicine*, vol. 142, no. 2, pp. 253–262, 2018.

[4] I. S. Sehgal, S. Dhooria, A. N. Aggarwal, and R. Agarwal, "Impact of rapid on-site cytological evaluation (ROSE) on the diagnostic yield of transbronchial needle aspiration during mediastinal lymph node sampling: systematic review and meta-analysis," *Chest*, vol. 153, no. 4, pp. 929–938, 2018.

[5] V. Mallya, S. P. Kumar, P. Meganathan, S. Shirkumar, and R. Mehta, "The utility of ROSE (rapid on-site evaluation) in endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA): is the picture rosy?", *Journal of Cytology*, vol. 32, no. 4, pp. 230–233, 2015.

[6] J. H. Austin and M. B. Cohen, "Value of having a cytopathologist present during percutaneous fine-needle aspiration biopsy of lung: report of 55 cancer patients and metaanalysis of the literature," *American Journal of Roentgenology*, vol. 160, no. 1, pp. 175–177, 1993.

[7] R. G. Pastorello, C. Destefani, P. H. Pinto et al., "The impact of rapid on-site evaluation on thyroid fine-needle aspiration biopsy: a 2-year cancer center institutional experience," *Cancer Cytopathology*, vol. 126, no. 10, pp. 846–852, 2018.

[8] A. Fassina, M. Corradin, D. Zardo, R. Cappelletto, F. Corbetti, and M. Fassan, "Role and accuracy of rapid on-site evaluation of CT-guided fine needle aspiration cytology of lung nodules," *Cytopathology: Official Journal of the British Society for Clinical Cytology*, vol. 22, no. 5, pp. 306–312, 2011.

[9] S. Chandra, H. Chandra, and G. Sindhwani, "Role of rapid on-site evaluation with cyto-histopathological correlation in diagnosis of lung lesion," *Journal of Cytology*, vol. 31, no. 4, pp. 189–193, 2014.

[10] M. Bonifazi, M. Sediari, M. Ferretti et al., "The role of the pulmonologist in rapid on-site cytopathologic evaluation of transbronchial needle aspiration: a prospective study," *Chest*, vol. 145, no. 1, pp. 60–65, 2014.

[11] D. P. Steinfurt, T. L. Leong, I. F. Laska, A. Beatty, A. Trau, and L. B. Irving, "Diagnostic utility and accuracy of rapid on-site evaluation of bronchoscopic brushings," *The European Respiratory Journal*, vol. 45, no. 6, pp. 1653–1660, 2015.

[12] W. D. Travis, E. Brambilla, M. Noguchi et al., "International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma," *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, vol. 6, no. 2, pp. 244–285, 2011.

[13] Z. A. Hafajee and A. S. Leong, "Ultra-rapid microwave-stimulated tissue processing with a modified protocol incorporating microwave fixation," *Pathology*, vol. 36, no. 4, pp. 325–329, 2004.

[14] Y. C. Chang, C. J. Yu, W. J. Lee et al., "Imprint cytology improves accuracy of computed tomography-guided percutaneous transthoracic needle biopsy," *The European Respiratory Journal*, vol. 31, no. 1, pp. 54–61, 2008.

[15] E. Mazza, C. Maddau, A. Ricciardi, M. Falchini, M. Matucci, and Ciarpallini, T., "On-site evaluation of percutaneous CT-guided fine needle aspiration of pulmonary lesions. A study of 321 cases," *La Radiologia Medica*, vol. 110, no. 3, pp. 141–148, 2005.

[16] G. Aviram, J. Greif, A. Man et al., "Diagnosis of intrathoracic lesions: are sequential fine-needle aspiration (FNA) and core needle biopsy (CNB) combined better than either investigation alone?", *Clinical Radiology*, vol. 62, no. 3, pp. 221–226, 2007.

[17] A. Koul, A. C. Baxi, R. Shang et al., "The efficacy of rapid on-site evaluation during endoscopic ultrasound-guided fine needle aspiration of pancreatic masses," *Gastroenterology Report*, vol. 6, no. 1, pp. 45–48, 2018.

[18] S. Gasparini, "It is time for this ‘ROSE’ to flower," *Respiration; International Review of Thoracic Diseases*, vol. 72, no. 2, pp. 129–131, 2005.

[19] A. V. Cardoso, I. Neves, A. Magalhaes, M. Sucena, H. Barroca, and G. Fernandes, "The value of rapid on-site evaluation during EBUS- TBNA," *Revista Portuguesa de Pneumologia (English Edition)*, vol. 21, no. 5, pp. 253–258, 2015.

[20] S. K. Jeffus, A. K. Joiner, E. R. Siegel et al., "Rapid-on-site evaluation of EBUS-TBNA specimens of lymph nodes: comparative analysis and recommendations for standardization," *Cancer Cytology*, vol. 123, no. 6, pp. 362–372, 2015.

[21] R. L. Schmidt, B. L. Witt, L. E. Lopez-Calderon, and L. J. Layfield, "The influence of rapid onsite evaluation on the adequacy rate of fine-needle aspiration cytology: a systematic review and meta-analysis," *American Journal of Clinical Pathology*, vol. 139, no. 3, pp. 300–308, 2013.

[22] S. Ravaiol, S. Bravaccini, M. M. Tumed, F. Pironi, P. Candoli, and M. Puccetti, "Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytopathology to histology," *Oncotarget*, vol. 8, no. 7, pp. 11199–11205, 2017.

[23] B. Celik, T. Bulut, and A. Khoor, "Subtyping of non-small cell lung cancer by cytology specimens: a proposal for resource-poor hospitals," *CytoJournal*, vol. 16, p. 8, 2019.

[24] B. Celik, A. Khoor, T. Bulut, and A. Nassar, "Rapid on-site evaluation has high diagnostic yield differentiating adenocarcinoma vs squamous cell carcinoma of non-small cell lung carcinoma, not otherwise specified subgroup," *Pathology & Oncology Research*, vol. 21, no. 1, pp. 167–172, 2015.

[25] N. Tochigi, S. Dacic, and N. P. Otori, "Bronchoscopic and transthoracic cytology and biopsy for pulmonary nonsmall cell carcinomas: performance characteristics by procedure and tumor type," *Diagnostic Cytopathology*, vol. 40, no. 8, pp. 659–663, 2012.

[26] H. A. Domanski, *Atlas of Fine Needle Aspiration Cytology*, Springer, 2014.

[27] "Book Review: Diagnosing non-small cell carcinoma in small biopsy and cytology," *Journal of the American Society of Cytopathology*, vol. 4, no. 6, pp. XII–XIII, 2015.

[28] J. Feng, Q. Li, Y. Shi, and K. Wang, "Rapid on-site evaluation (ROSE) in diagnostic interventional pulmonology: introduction and detailed methods," in *Rapid On-Site Evaluation (ROSE) in Diagnostic Interventional Pulmonology: Volume 1: Infectious Diseases*, J. Feng, X. Li, P. Li, Q. Li, and Y. Shi, Eds., Springer Singapore, Singapore, pp. 1–9, 2019.

[29] M. L. Plit, A. P. Haven, A. Hodges et al., "Rapid cytological analysis of endobronchial ultrasound-guided aspirates in sarcoidosis," *European Respiratory Journal*, vol. 42, no. 5, pp. 1302–1308, 2013.